Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
CCDC6
Description:
A human protein-coding gene involved in cellular processes and studied in cancer biology, including tumor development and DNA repair.
Related topics:
Lung Cancer Treatments and Mutations (16%),
PARP inhibition in cancer therapy (15%)
Wikidata ID:
wiki/Q18032709
OpenAlex ID:
keywords/ccdc6
Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma
2008
·
Krystian Jazdzewski
, Elizabeth L. Murray
, et al.
·
Proceedings of the National Academy of Sciences
·
906
Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer’s disease risk genes
2021
·
Jeremy Schwartzentruber
, Sarah Cooper
, et al.
·
Nature Genetics
·
578
PDF
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
2022
·
Vivek Subbiah
, Philippe A. Cassier
, et al.
·
Nature Medicine
·
269
PDF
Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).
2019
·
Justin F. Gainor
, Dae Ho Lee
, et al.
·
Journal of Clinical Oncology
·
120
A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
2013
·
Oliver Gautschi
, Thilo Zander
, et al.
·
Journal of Thoracic Oncology
·
104
DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells
2010
·
M Gandhi
, L W Dillon
, et al.
·
Oncogene
·
98
Differential 14-3-3 Affinity Capture Reveals New Downstream Targets of Phosphatidylinositol 3-Kinase Signaling
2009
·
Fanny Dubois
, Franck Vandermoere
, et al.
·
Molecular & Cellular Proteomics
·
82
PDF
Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
2020
·
Justin F. Gainor
, Giuseppe Curigliano
, et al.
·
Journal of Clinical Oncology
·
81
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
2017
·
Francesco Morra
, Francesco Merolla
, et al.
·
Oncotarget
·
75
PDF
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs
2016
·
Umberto Malapelle
, Francesco Morra
, et al.
·
Lung Cancer
·
69
Transcript Level Modulates the Inherent Oncogenicity of RET/PTC Oncoproteins
2009
·
Douglas S. Richardson
, Taranjit S. Gujral
, et al.
·
Cancer Research
·
60
Decoding heterogeneous single-cell perturbation responses
2025
·
Bicna Song
, Dingyu Liu
, et al.
·
Nature Cell Biology
·
58
New therapeutic perspectives in CCDC 6 deficient lung cancer cells
2014
·
Francesco Morra
, Chiara Luise
, et al.
·
International Journal of Cancer
·
57
MicroRNA-146b-5p as an oncomiR promotes papillary thyroid carcinoma development by targeting CCDC6
2018
·
Meng Jia
, Yang Shi
, et al.
·
Cancer Letters
·
56
FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC
2015
·
Francesco Morra
, Chiara Luise
, et al.
·
Oncotarget
·
55
PDF
RETRACTED: Loss of CCDC6, the First Identified RET Partner Gene, Affects pH2AX S139 Levels and Accelerates Mitotic Entry upon DNA Damage
2012
·
Francesco Merolla
, Chiara Luise
, et al.
·
PLoS ONE
·
53
PDF
Current management of RET rearranged non-small cell lung cancer
2020
·
Thomas E Stinchcombe
·
Therapeutic Advances in Medical Oncology
·
48
CCDC6: the identity of a protein known to be partner in fusion
2017
·
Aniello Cerrato
, Francesco Merolla
, et al.
·
International Journal of Cancer
·
48
PDF
Identification of RET fusions in a Chinese multicancer retrospective analysis by next‐generation sequencing
2021
·
Minke Shi
, Weiran Wang
, et al.
·
Cancer Science
·
47
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer
2019
·
Francesco Morra
, Francesco Merolla
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
47
PDF
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1
2010
·
V Leone
, G Mansueto
, et al.
·
Oncogene
·
46
Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD
2019
·
Xiaotian Sun
, Parvaneh Jefferson
, et al.
·
Molecular Cancer Research
·
43
Molecular Changes during Neurodevelopment following Second-Trimester Binge Ethanol Exposure in a Mouse Model of Fetal Alcohol Spectrum Disorder: From Immediate Effects to Long-Term Adaptation
2014
·
Katarzyna Mantha
, Benjamin I. Laufer
, et al.
·
Developmental Neuroscience
·
43
Focus on Molecules: The cystine/glutamate exchanger (System xc−)
2010
·
Julie C. Lim
, Paul J. Donaldson
·
Experimental Eye Research
·
42
Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors
2018
·
Vivek Subbiah
, Matthew Taylor
, et al.
·
Cancer Research
·
34
Show more works
View as search
Works count:
184
Citation count:
3,818
Year
Topic
Type